Foundation for Angelman Syndrome Therapeutics

Call Website

Foundation for Angelman Syndrome Therapeutics FAST is the leading patient advocacy organization working to cure Angelman syndrome. FAST reserves the right to modify the guidelines, if needed. No advertising.

Our goal is to drive forward transformative research and development programs for those living with Angelman syndrome—regardless of age or genotype. Page Rules:
Thank you for your interest in the Foundation for Angelman Syndrome Therapeutics (FAST). FAST was founded with a single, critical mission: to cure Angelman syndrome. The organization, founded in 2008, is the largest non-governmental funder of Angelman syndrome research, and today has a global presence. We designed this page as a platform to share research, resources, and information to our Angelman syndrome community and those interested in supporting our mission to cure AS. We have outlined community guidelines to ensure that conversations remain respectful and are aligned to Facebook’s official terms of use and community standards. Your acceptance of these terms is made by the use of this page. To ensure that this page remains a positive resource, we have developed the following page rules. These rules are guidelines for comments on our page, and we reserve the right to delete any comments or threads that violate these rules:

1. Be kind and courteous. We're all in this together to create a positive, informative, and respectful environment. Healthy debates are natural, but kindness is required.

2. No disrespectful comments. Bullying of any kind isn't allowed and degrading comments will not be tolerated. Do not post profane, defamatory, offensive or violent language.

3. Do not share personal and private information. This is a public page and information that is shared will be publicly accessible.

4. Don’t use this page for advertising your or someone else’s business, page or website.

5. Do not disclose confidential, nonpublic or proprietary business information that may compromise the confidentiality and security of FAST or any other person or company.

6. Do not post attacks or negative comments regarding groups. Any comments meant to harass, disparage, threaten or abuse an individual will be removed. FAST will do its best to respond to any questions or concerns in a timely fashion; however, at times, FAST may choose to respond privately or not to respond at all.

11/02/2026

What is next for Angelman syndrome research?

It's one of the most important questions facing the Angelman syndrome community. And this week, researchers, clinicians, and industry leaders will come together to share the latest developments at the 2026 FAST Global Science Summit.

From emerging scientific approaches to updates on investigational therapies and clinical trials, the Summit offers an opportunity to hear directly from the experts working to advance treatments for Angelman syndrome.

You do not have to be in Orlando to be part of it.

Join us virtually on November 6-7 to hear the presentations, explore the research underway, and gain a better understanding of where the science is headed.

Register to attend virtually: https://cvent.me/9obWr5

If English not your preferred language, live translations will be available in over 60 languages.

Congratulations to our TEAM KICK-AS runners who took on the Venice Half Marathon last weekend in honor of Jaxson and Leo...
11/01/2026

Congratulations to our TEAM KICK-AS runners who took on the Venice Half Marathon last weekend in honor of Jaxson and Leo, two individuals living with Angelman syndrome.

What made this team especially meaningful was the mix of people who came together: parents, grandparents, siblings, and extended family. Even Angelman syndrome researcher Claudia Medeiros was inspired to join the team, taking her commitment to the community beyond the lab and onto the racecourse!

A big congratulations and thank you to Chad Dunigan, Bryce Dunigan, Gage Dunigan, Rhys Votano, Anita and Luca Belgiorno, Matteo Belgiorno, and Jacqueline Whiteford, Cadee Etemadi, and Claudia Medeiros. Together they raised over $8,000 for Angelman syndrome research!

You don't have to run a marathon to make a difference. Discover the many ways you can fundraise for FAST: https://cureangelman.org/get-involved/fundraising

Some of the most important decisions about the future of Angelman syndrome research are being made right now. Which prom...
11/01/2026

Some of the most important decisions about the future of Angelman syndrome research are being made right now. Which promising ideas receive funding? Which scientific questions get answered? Which approaches have the resources to take the next step?

The opportunities are real. So is the need for continued funding.

On November 7, FAST’s Day of Giving is an opportunity to invest in the research that comes next.

Wherever you are in the world, your support can help turn promising science into meaningful treatments.

It takes all of us.

Save the date: November 7

Maddie's Mission celebrated another record-breaking Block Party, raising an incredible $296,000! Since its inception in ...
10/30/2026

Maddie's Mission celebrated another record-breaking Block Party, raising an incredible $296,000!

Since its inception in 2022, this dedicated community has raised more than $1.5M in honor of Maddie. FAST is incredibly grateful to be among the recipients of this generosity and to share in the mission of advancing treatments and a cure for Angelman syndrome.

We refreshed the FAST website to make important information easier to find, with improved navigation, expanded resources...
10/28/2026

We refreshed the FAST website to make important information easier to find, with improved navigation, expanded resources, and new features designed to better serve the Angelman syndrome community.

🔹One exciting addition is our new trial finder tool🔹

For the first time, you can search and filter Angelman syndrome clinical trials and observational studies by recruiting status, age group, location, genotype, and therapeutic approach, making it easier to explore research opportunities relevant to your family.

Explore cureangelman.org

What a weekend for TEAM KICK-AS in Dublin! 🍀 Congratulations to runners Thomas Kennedy and Johanna Kennedy, who complete...
10/27/2026

What a weekend for TEAM KICK-AS in Dublin! 🍀

Congratulations to runners Thomas Kennedy and Johanna Kennedy, who completed the Dublin Marathon in honor of their daughter, Anabella, who lives with Angelman syndrome. Joining them for the 26.2-miles race were their friends Michael Mellotte and Graham Coffey.

Together they raised over $10,000 for Angelman syndrome research!

Thomas, Johanna, Michael, and Graham, thank you for the miles, the dedication, and bringing so many people together in support of FAST. And to everyone who donated and cheered them on, thank you for making this such a success. đź’™

Want to get involved? There are so many ways you can help fuel Angelman syndrome research. Learn more: https://cureangelman.org/get-involved/fundraising

Newborn screening is one of the great public health success stories. Nearly every baby born in the U.S. is screened at b...
10/26/2026

Newborn screening is one of the great public health success stories. Nearly every baby born in the U.S. is screened at birth for dozens of serious conditions.

Angelman syndrome isn’t one of them.

For most families, the answer comes later, after missed milestones, specialist visits, and months or years of uncertainty. That’s time without a diagnosis, without the right support, and without a path to treatment.

Newborn screening is evolving, and those changes will shape what is possible for future families. HRSA is reconsidering how new conditions are reviewed, and a new national workgroup meets for the first time this December.

FAST is making sure Angelman syndrome is part of of the conversation. Over the past few weeks, FAST’s Niki Armstrong brought the Angelman syndrome voice to newborn screening meetings with policymakers, researchers, and public health labs. Thank you to , , , and for convening these conversations.

LAST CHANCE: Find your people. Bring your questions. Leave feeling informed, connected, and supported. 💙 Whether you’re ...
10/24/2026

LAST CHANCE: Find your people. Bring your questions. Leave feeling informed, connected, and supported. đź’™

Whether you’re looking for answers, new friendships, or a renewed sense of energy, there’s a place for you here.

Register by October 27 and be part of a weekend to remember: https://cvent.me/gq0V3w

Rain couldn’t dampen this community’s spirit! 💙 A huge thank-you to the Granville Angels Foundation for hosting its annu...
10/23/2026

Rain couldn’t dampen this community’s spirit! 💙

A huge thank-you to the Granville Angels Foundation for hosting its annual Co****le for a Cause fundraiser! Despite a downpour that lasted throughout the event, approximately 150 people—including 28 teams, plenty of spectators, and seven Angelman syndrome families—showed up to make a difference.

Together, they raised more than $34,000! 🎉

To the Granville Angels Foundation and everyone who braved the rain: thank you for showing what’s possible when a community comes together.

How do we make sure the patient voice helps shape the future of rare disease drug development? That question is especial...
10/16/2026

How do we make sure the patient voice helps shape the future of rare disease drug development? That question is especially timely.

On Wednesday, the FDA announced its new Rare Disease Framework Initiative, which includes a commitment to incorporating patient perspectives earlier and at key milestones throughout drug development and review.

Today, FAST Chief Science Officer Dr. Allyson Berent will join a national discussion focused on exactly that challenge: understanding where patients have a voice in medical product development and how their involvement can be strengthened.

The meeting, Patient Voice in Rare Disease Medical Product Development, is being convened by the Reagan-Udall Foundation for the FDA, in collaboration with the FDA.

For FAST, this is an opportunity to share lessons from Angelman syndrome, where families have helped shape research priorities, clinical trial readiness, and the understanding of what meaningful treatment outcomes look like.

As approaches to rare disease drug development evolve, the experiences of patients and families are essential to getting them right.

Join the conversation virtually today, October 16, from 1–5 p.m. ET.: https://reaganudall.org/news-and-events/events/patient-voice-rare-disease-medical-product-development

Address

Austin, TX

Alerts

Be the first to know and let us send you an email when Foundation for Angelman Syndrome Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Sponsored

Share